Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;36(5):e14616.
doi: 10.1111/ctr.14616. Epub 2022 Feb 22.

Suppression of tumorigenicity-2 (ST2) is a promising biomarker in heart transplantation

Antonella Galeone  1 , Joe-Elie Salem  2 , Guillaume Lebreton  1 , Guillaume Coutance  1 , Lee Nguyen  2 , Jean Sébastien Hulot  3 , Fabrice Atassi  3 , Marco Bega  1 , Pascal Leprince  1 , Shaida Varnous  1
Affiliations

Suppression of tumorigenicity-2 (ST2) is a promising biomarker in heart transplantation

Antonella Galeone et al. Clin Transplant. 2022 May.

Abstract

Background: To evaluate the association between donors' and recipients' serum levels of soluble ST2 (sST2) and recipients' outcome after heart transplantation (HT).

Methods: Blood samples were collected in 50 heart donors before organ procurement and in 50 recipients before HT (D0), a week after HT (D7) and at every first year's endomyocardial biopsy (EMB); sST2 levels were evaluated by ELISA.

Results: Donors who sustained a cardiac arrest, had significantly higher sST2 levels. Recipients on national high emergency waiting list had significantly higher preoperative sST2 levels compared to recipients who did not. Recipients with postoperative sepsis or continuous renal replacement therapy had significantly higher sST2 levels at D7. Recipients who needed a postoperative ECMO for allograft dysfunction had significantly higher sST2 levels in their corresponding donors. Recipients who died during the hospitalization after the transplantation had significantly higher sST2 levels at D7 compared to recipients who did not. No difference was observed in sST2 levels in recipients who had mild allograft rejection and recipient who did not.

Conclusions: Higher sST2 levels in donors are associated to allograft dysfunction requiring ECMO in recipients; higher postoperative sST2 levels in recipients are associated with in-hospital mortality.

Keywords: biomarker; heart donor; heart graft dysfunction.

PubMed Disclaimer

References

REFERENCES

    1. Tominaga S. A putative protein of a growth specific cDNA from BALB/c 3T3 cells is highly similar to the extracellular portion of mouse interleukin-1 receptor. FEBS Lett. 1989;258:301-304.
    1. Bergers G, Reikerstorfer A, Braselmann S, et al. Alternative promoter usage of the fos-responsive gene Fit-1 generates RNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994;13:1176-1188.
    1. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1- like cytokine that signals via the IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-490.
    1. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277-281.
    1. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2003;124:1206-1214.

Publication types

Substances

LinkOut - more resources